Cargando…
High incidence of major bleeding with off-label use of edoxaban
In clinical practice, edoxaban is sometimes prescribed for off-label use based on the hypothesis that it is as safe and effective as warfarin. However, there is limited safety information on off-label use due to lack of clinical trial. We aimed to analyze the tolerability of off-label use of edoxaba...
Autores principales: | Fukui, Rika, Hira, Daiki, Kunitsu, Yuki, Isono, Tetsuichiro, Tabuchi, Yohei, Ikuno, Yoshihiro, Ueshima, Satoshi, Itoh, Hideki, Tanaka, Toshihiro, Terada, Tomohiro |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
the Society for Free Radical Research Japan
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8611372/ https://www.ncbi.nlm.nih.gov/pubmed/34857995 http://dx.doi.org/10.3164/jcbn.21-9 |
Ejemplares similares
-
Time until onset of acute kidney injury by combination therapy with “Triple Whammy” drugs obtained from Japanese Adverse Drug Event Report database
por: Kunitsu, Yuki, et al.
Publicado: (2022) -
Urine volume to hydration volume ratio is associated with pharmacokinetics of high‐dose methotrexate in patients with primary central nervous system lymphoma
por: Isono, Tetsuichiro, et al.
Publicado: (2021) -
Edoxaban: Minor bleeding: case report
Publicado: (2022) -
Risk factors for gastrointestinal bleeding in patients with gastrointestinal cancer using edoxaban
por: Bosch, Floris T. M., et al.
Publicado: (2021) -
Prediction and Implications of Edoxaban-Associated Bleeding in Patients after Critical Illness
por: Mikami, Ryusei, et al.
Publicado: (2023)